Virtual Library
Start Your Search
Kaye J Williams
Author of
-
+
P1.13 - Targeted Therapy (Not CME Accredited Session) (ID 945)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.13-35 - Hypoxia Mapping Using Oxygen-Enhanced MRI in Lung Cancer (ID 14283)
16:45 - 18:00 | Author(s): Kaye J Williams
- Abstract
Background
Oxygen deprivation (hypoxia) is associated with worse non-small cell lung cancer (NSCLC) outcomes and predicts poor response to NSCLC treatments, including radiotherapy. There is an unmet need to develop non-invasive hypoxia biomarkers. We report the first preclinical and clinical evidence that oxygen-enhanced MRI (OE-MRI) can map and quantify therapy-induced change in NSCLC hypoxia.
a9ded1e5ce5d75814730bb4caaf49419 Method
In the preclinical study, radiation-induced changes in OE-MRI were first examined in a Calu-6 xenograft model of NSCLC. Tumours received a single 10Gy fraction of radiotherapy (n=9), chemoradiotherapy (5 x 2Gy fractions plus cisplatin; n=6) or control (n=9). Mice were imaged longitudinally using a multi-parametric MRI protocol (diffusion-weighted imaging (DWI), OE and dynamic contrast-enhanced (DCE)-MRI) at days 0, 3, 6 and 10 in all groups and then at day 13 (control), day 18 and 25 (radiotherapy) and day 18 (chemoradiotherapy). Pathology was obtained at cull in imaged mice and in a separate Calu6 cohort treated with a single 10Gy radiotherapy fraction (n=6) or control (n=9) at day 10. In the clinical study, twenty three stage I-IV NSCLC patients underwent an identical multi-parametric MRI for protocol development (n=6), twice prior to radiotherapy (n=10) and after 14±4 radiotherapy fractions (n=12). In all tumours we quantified the validated MRI hypoxia biomarker perfused oxygen-refractory (Oxy-R), which identifies absence of OE-MRI signal change in perfused tumour.
4c3880bb027f159e801041b1021e88e8 Result
By day 10, perfused Oxy-R (hypoxic) volume decreased relative to control in xenografts treated with either radiotherapy (p=0.029) or fractionated chemoradiotherapy (p=0.047). Hypoxia modification persisted in chemoradiotherapy treated tumors to day 16 and in radiotherapy treated tumors to day 22 (both p<0.001). Pimonidazole immunohistochemistry at day 10 showed lower hypoxic fraction in tumors treated with radiotherapy (p=0.026), relative to time matched controls. In addition, imaged xenografts also showed lower hypoxic fractions in radiotherapy (p=0.042) and chemoradiotherapy (p=0.041) treated tumors, relative to size matched control at cull. In the clinical study, OE-MRI was safe, feasible and well-tolerated. Perfused Oxy-R (hypoxic) volume demonstrated excellent repeatability with interclass correlation coefficient of 0.961 (95% CI 0.858-0.990). Visual inspection revealed that MRI hypoxia maps were spatially repeatable across a range of tumour and hypoxic volumes. In the absence of volumetric tumour change, perfused Oxy-R (hypoxic) volume decreased at mid-treatment (3.23 cm3 (95% CI 0-9.41 cm3)), compared to baseline (4.16 cm3 (95% CI 0-10.6 cm3)); p=0.0150.
8eea62084ca7e541d918e823422bd82e Conclusion
Our findings support using OE-MRI to detect and monitor hypoxia in clinical trials of hypoxia-modifying therapies or radiotherapy dose painting studies in patients with NSCLC.
6f8b794f3246b0c1e1780bb4d4d5dc53